A new class of antiplatelet therapy drug pending U.S. Food and Drug Administration (FDA) clearance may offer greater benefits over clopidogrel (Plavix) the current standard of therapy. The new drug also offers the ability to have its effects reversed quickly. In late July, the FDA Cardiovascular and Renal Drugs Advisory Committee voted 7-1 recommending final approval of ticagrelor (Brilinta) for the reduction of thrombotic events in patients with acute coronary syndromes (ACS). While the FDA is not required to follow the approval recommendation from the committee, the agency takes the advice into consideration when rendering its final decisions. The FDA was expected to make a final decision by September, but recently granted an extension until December 16 for further review. According to the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study of more than 18,000 patients, ticagrelor was superior to clopidogrel in the long-term reduction of cardiovascular events. Data showed ticagrelor reduced cardiovascular death, heart attacks and stroke over clopidogrel (9.8 vs. 11.7 percent), without an increase in overall major bleeding (11.6 vs. 11.2 percent). Unlike clopidogrel or prasugrel (Effient), approved a year ago, ticagrelor is the first reversible oral antiplatelet drug. This may offer benefits for patients who need to undergo surgery or suffer trauma. Current protocols usually call for patients to stop taking clopidogrel several days prior to surgery to prevent major bleeding complications. Meaningful Use Finally Defined The 2009 Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), part of the federal stimulus package, was supposed to inject more than $20 billion into healthcare information technology (IT). However, a year, later very little of that money has been spent because the government stipulated that funds should only be used for technology meeting the nebulous definition of “meaningful use.” In July, final meaningful use regulations were announced by the Centers for Medicare and Medicaid (CMS) and the Office of the National Coordinator for Health Information Technology (ONC). These rules define the incentive payments program attached to healthcare technology. The rules also outlined standards and certification requirements for electronic medical record (EMR) systems. The goal of HITECH is to achieve widespread adoption of EMRs by 2014. CMS will administer an incentive payments program that will make significant bonus payments available to eligible healthcare providers who adopt and demonstrate meaningful use of certified EMRs. For details and a complete listing of the new regulations, visit the U.S. Department of Health and Human Services health IT site at: http://healthit.hhs.gov/portal/server.pt?open=512&objID=2996&mode=2. Sorry about the long link, but it is the federal government after all. Included in this issue of Diagnostic and Interventional Cardiology is a comparison chart for cardiovascular information systems (CVIS) and cardiovascular picture archiving and communications systems (PACS), starting on page 5. There has been a big question among healthcare IT vendors as to how meaningful use would effect their products. However, all the large healthcare vendors have given commitments to their customers that they will provide whatever is needed to meet any new federal requirements – as if they have a choice in the matter if they want to stay in business. Hybrid Planning Needs Clinical Engineers The July/August issue of DAIC included a story about what is needed when planning a hybrid cath lab/operating room. Frank E. Nickells Jr., CBET, clinical engineering support manager, CHI/Centura Health Supply Chain Management, responded to the story and said clinical engineers were missing on a list of key players to include on a planning committee. He wrote, “All key persons listed are necessary, but clinical engineering is at least as important as facilities engineering. Facilities engineering is important for planning this venture, but clinical engineers will live with and support this product for the next seven to 10 years through either direct support or contract support.” Nickells said facility engineers do not affect down-time and revenue generation during the hybrid’s operational life, whereas clinical engineers do. He said they also should be involved in the purchasing phase of the project. The Web link to last month’s story on how to plan for a hybrid lab installation can be found at www.dicardiology.net/node/37175.
Feature | September 15, 2010| Dave Fornell
New Antiplatelet Drug May Offer Benefits Over Clopidogrel
News | Implantable Cardiac Monitor (ICM)| April 19, 2017
Murj Inc., a digital health company that helps manage implantable cardiac device data, announced more than $4.5 million...
News | Clinical Decision Support| April 19, 2017
Siemens Healthineers plans to expand its Population Health Management (PHM) portfolio with the acquisition of Medicalis...
Feature | Cardiac Imaging| April 18, 2017 | Dave Fornell
As part of U.S. healthcare reform efforts, starting Jan.
Feature | HRS| April 14, 2017
April 14, 2017 — The Heart Rhythm Society (HRS) has announced its late-breaking clinical trials at its annual meeting
Sponsored Content | Videos | Analytics Software| April 13, 2017
The shift to value-based payment models requires focused attention on quality and cost.
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
Feature | Atrial Fibrillation| March 29, 2017
March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K,...
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
News | Chronic Total Occlusion (CTO)| March 29, 2017 | Dave Fornell
March 29, 2017 — In patients with a complete, persistent arterial blockage, medication alone was found to be equal to
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...